Company intelligence / Profile preview

Coelum

Not specified, New Jersey, United Statescoelum.com ↗

Ownership: Private
Employees: ~11
Development stage: Other

Overview

CAEL-101, the lead program, is a novel monoclonal antibody developed for AL amyloidosis. It reached Phase 3 clinical trials with about 400 patients enrolled globally. CAEL-101 has received Orphan Drug Designation from both the FDA and European Commission and Fast Track Designation from the FDA for AL amyloidosis.

Therapeutic areas: Hematology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Partnerships

Alexion Pharmaceuticals/AstraZenecaFortress Biotech

Beyond the preview

Go deeper on Coelum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coelum.

Explore the full profile